Protide

NuCana Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, August 16, 2023
Dicarboxylic acid, Docetaxel, Bevacizumab, Therapy, FOLFIRI, Oxaliplatin, Lung cancer, Protide, Lung, NCNA, Patient, Colorectal cancer, Melanoma, Irinotecan, Pharmaceutical industry

EDINBURGH, United Kingdom, Aug. 16, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the second quarter ended June 30, 2023 and provided an update on its broad clinical development program with its transformative ProTide therapeutics.

Key Points: 
  • EDINBURGH, United Kingdom, Aug. 16, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the second quarter ended June 30, 2023 and provided an update on its broad clinical development program with its transformative ProTide therapeutics.
  • As of June 30, 2023, NuCana had cash and cash equivalents of £24.6 million compared to £31.0 million at March 31, 2023 and £41.9 million at December 31, 2022.
  • NuCana continues to advance its various clinical programs and reported a net loss of £5.4 million for the quarter ended June 30, 2023, as compared to a net loss of £3.9 million for the quarter ended June 30, 2022.
  • Basic and diluted loss per share was £0.10 for the quarter ended June 30, 2023, as compared to £0.07 per share for the comparable quarter ended June 30, 2022.

NuCana Reports Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, November 16, 2022
Protide, Immunogenic cell death, PD-1, NSCLC, Docetaxel, Oxaliplatin, European Society for Medical Oncology, Large-cell lung carcinoma, Melanoma, Patient, Neoplasm, Adenocarcinoma, Pembrolizumab, Oncology, Irinotecan, Thymidylate synthase, NCNA, Commencement (album), Security (finance), ESMO, Colorectal cancer, Cancer, Therapy, Pemetrexed, Bevacizumab, Organic acid, Pharmaceutical industry, Medical imaging, Food delivery

EDINBURGH, United Kingdom, Nov. 16, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the third quarter ended September 30, 2022 and provided an update on its broad clinical program with its transformative ProTide therapeutics.

Key Points: 
  • EDINBURGH, United Kingdom, Nov. 16, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the third quarter ended September 30, 2022 and provided an update on its broad clinical program with its transformative ProTide therapeutics.
  • As of September 30, 2022, NuCana had cash and cash equivalents of 50.8 million compared to 46.5 million as of June 30, 2022 and 60.3 million at December 31, 2021.
  • NuCana continues to advance its various clinical programs and reported a net loss of 4.5 million for the quarter ended September 30, 2022, as compared to a net loss of 8.0 million for the quarter ended September 30, 2021.
  • Basic and diluted loss per share was 0.09 for the quarter ended September 30, 2022, as compared to 0.15 per share for the quarter ended September 30, 2021.

NuCana to Present at the Jefferies London Healthcare Conference

Retrieved on: 
Tuesday, November 8, 2022
GLOBE, Private Securities Litigation Reform Act, Forward-looking statement, U.S. Securities and Exchange Commission, SEC, NASDAQ, Goal, PD-1, Company, Cancer, Pembrolizumab, Terminology, Conference, Patient, Protide, Security (finance), NCNA, Pharmaceutical industry

EDINBURGH, United Kingdom, Nov. 08, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies London Healthcare Conference.

Key Points: 
  • EDINBURGH, United Kingdom, Nov. 08, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies London Healthcare Conference.
  • NUC-3373 is a new chemical entity derived from the nucleoside analog 5-fluorouracil, a widely used chemotherapy agent.
  • NUC-3373, in combination with other agents, is in a Phase 1b/2 study in patients with metastatic colorectal cancer.
  • NuCana has also initiated a randomized Phase 2 study of NUC-3373, in combination with other agents, for the second-line treatment of patients with advanced colorectal cancer.

NuCana Presents Positive Data on NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting 2022

Retrieved on: 
Wednesday, October 26, 2022
ICD, SEC, Company, Squamous cell carcinoma, Security (finance), U.S. Securities and Exchange Commission, Bevacizumab, Damage-associated molecular pattern, NASDAQ, CRC, Private Securities Litigation Reform Act, DNA, Cancer, Lung cancer, Goal, Forward-looking statement, DNA repair, Terminology, Pemetrexed, Large-cell lung carcinoma, Immunotherapy, Docetaxel, Protide, Pembrolizumab, Patient, PD-1, Immunogenic cell death, GLOBE, FOLFIRI, Thymidylate synthase, NCNA, Adenocarcinoma, Vaccine, Pharmaceutical industry, NSCLC

BARCELONA, Spain, Oct. 26, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced non-clinical data from two poster presentations at the 34th EORTC-NCI-AACR Annual Meeting being held from October 26 to 28, 2022.

Key Points: 
  • BARCELONA, Spain, Oct. 26, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced non-clinical data from two poster presentations at the 34th EORTC-NCI-AACR Annual Meeting being held from October 26 to 28, 2022.
  • NUC-3373 generated high intracellular levels of the anti-cancer metabolite FUDR-MP, resulting in TS inhibition, and the DNA-targeting metabolite, FUDR-TP.
  • These data highlight that NUC-3373 may be an effective treatment for non-small cell lung cancer (NSCLC) regardless of histological subtype and basal TS expression.
  • NUC-3373 causes NSCLC cells to release damage associated molecular patterns (DAMPs), molecular signals that activate immune cells leading to immunogenic cell death (ICD).

NuCana Presents Promising Data on NUC-7738 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022

Retrieved on: 
Monday, September 12, 2022
NCNA, Polyadenylation, Cordycepin, Safety, Adenosine, Edinburgh Cancer Research Centre, ADA, Protide, Gene, Company, European Society for Medical Oncology, Private Securities Litigation Reform Act, Melanoma, Forward-looking statement, U.S. Securities and Exchange Commission, Neoplasm, Patient, AES, Cancer, Oncology, Senior lecturer, Terminology, Goal, Transport, NASDAQ, RNA, Security (finance), GLOBE, Trae tha Truth, SEC, PD-1, Pembrolizumab, ESMO, Pharmaceutical industry, Medical imaging

PARIS, Sept. 12, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced data today from the ongoing NuTide:701 study of NUC-7738 in an oral presentation at the European Society for Medical Oncology (ESMO) Annual Meeting.

Key Points: 
  • PARIS, Sept. 12, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced data today from the ongoing NuTide:701 study of NUC-7738 in an oral presentation at the European Society for Medical Oncology (ESMO) Annual Meeting.
  • Data on NUC-7738 from the Phase 1 part of NuTide:701 showed encouraging signals of anti-tumor activity across a range of tumor types, particularly melanoma.
  • We are excited to further investigate the activity of NUC-7738 in melanoma and other tumor types.
  • We have begun enrolling patients into the Phase 2 part of the study and look forward to sharing these data.

NuCana Presents Favorable Data on NUC-3373 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022

Retrieved on: 
Monday, September 12, 2022
Safety, Thymidine, De novo, Uridine, Organic acid, Damage-associated molecular pattern, CRC, FOLFIRI, Patient, U.S. Securities and Exchange Commission, Oncology, Protide, NASDAQ, Dump, ESMO, NCNA, Oxaliplatin, Nucleotide, Bevacizumab, Cytokine, Diarrhea, Mucositis, Annual general meeting, Company, TS, FOLFOX, Toxic leukoencephalopathy, DNA, SEC, Growth hacking, European Society for Medical Oncology, Capecitabine, Irinotecan, Forward-looking statement, Acral lentiginous melanoma, Neutropenia, University of Washington School of Medicine, Associate professor, Goal, Progression-free survival, Security (finance), GLOBE, Immune system, Thymidylate synthase, Colorectal cancer, Private Securities Litigation Reform Act, Docetaxel, Cancer, Fred Hutchinson Cancer Research Center, Terminology, PD-1, University, PFS, Medical imaging, Pharmaceutical industry

PARIS, Sept. 12, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced data from the ongoing NuTide:302 study of NUC-3373 in combination with other agents at the European Society for Medical Oncology (ESMO) Annual Meeting being held from September 9 to 13, 2022.

Key Points: 
  • Data presented at ESMO describe NUC-3373 plus leucovorin in combination with either oxaliplatin (NUFOX) or irinotecan (NUFIRI) in the dose-finding part of the study.
  • The disease control rates for the NUFOX and NUFIRI regimens were 80% and 55%, respectively.
  • With these data, NuCana has established the recommended Phase 2 dose for NUC-3373 as part of NUFOX and NUFIRI regimens.
  • TS is required to convert uridine (specifically dUMP) to thymidine (specifically dTMP), one of the four nucleotides that comprise DNA.

NuCana Announces Presentations at the European Society for Medical Oncology (ESMO) Congress 2022

Retrieved on: 
Tuesday, September 6, 2022
European Society for Medical Oncology, Uridine, Security (finance), Protide, Diarrhea, Safety, Thymidine, RNA, Cancer, Gene, NASDAQ, Paris Expo Porte de Versailles, NCNA, Adenosine, Irinotecan, Nucleotide, ESMO, Dump, Thymidylate synthase, DNA, TS, SEC, Growth hacking, U.S. Securities and Exchange Commission, De novo, Goal, PD-1, GLOBE, Company, Cordycepin, Oncology, ADA, Oxaliplatin, Capecitabine, Neutropenia, Mucositis, Cell death, CRC, Congress, Polyadenylation, Terminology, Private Securities Litigation Reform Act, Transport, Forward-looking statement, Patient, Acral lentiginous melanoma, Medical imaging, Pharmaceutical industry

EDINBURGH, United Kingdom, Sept. 06, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced two presentations at the European Society for Medical Oncology (ESMO) Congress 2022 being held September 9-13, 2022 at the Paris Expo Porte de Versailles in Paris, France.

Key Points: 
  • EDINBURGH, United Kingdom, Sept. 06, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced two presentations at the European Society for Medical Oncology (ESMO) Congress 2022 being held September 9-13, 2022 at the Paris Expo Porte de Versailles in Paris, France.
  • TS is required to convert uridine (specifically dUMP) to thymidine (specifically dTMP), one of the four nucleotides that comprise DNA.
  • The inhibition of TS results in an imbalance in the ratio of dUMP and dTMP, thereby disrupting DNA synthesis and repair, ultimately leading to cancer cell death.
  • Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements.

NuCana to Participate in Citi's 17th Annual BioPharma Conference

Retrieved on: 
Wednesday, August 31, 2022
Security (finance), Protide, Cancer, NASDAQ, NCNA, SEC, U.S. Securities and Exchange Commission, Goal, PD-1, GLOBE, Citigroup, Conference, Company, Terminology, Private Securities Litigation Reform Act, Forward-looking statement, Patient, Pharmaceutical industry

EDINBURGH, United Kingdom, Aug. 31, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that management will host one-on-one meetings at Citi's 17th Annual BioPharma Conference.

Key Points: 
  • EDINBURGH, United Kingdom, Aug. 31, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that management will host one-on-one meetings at Citi's 17th Annual BioPharma Conference.
  • NUC-3373 is a new chemical entity derived from the nucleoside analog 5-fluorouracil, a widely used chemotherapy agent.
  • NUC-3373, in combination with other agents, is in a Phase 1b/2 study in patients with metastatic colorectal cancer.
  • NuCana has also initiated a randomized Phase 2 study of NUC-3373, in combination with other agents, for the second-line treatment of patients with advanced colorectal cancer.

NuCana Reports Second Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, August 17, 2022
Protide, U.S. Securities and Exchange Commission, Forward-looking statement, GLOBE, Private Securities Litigation Reform Act, SEC, Cancer, PD-1, Patent, Sofosbuvir, Politics of Poland, Security (finance), Neoplasm, Compliance, Patient, Irinotecan, Company, Therapy, Bevacizumab, NASDAQ, Organic acid, Goal, Commencement (album), NCNA, Colorectal cancer, Terminology, Renewable energy, Pharmaceutical industry, Food delivery

EDINBURGH, United Kingdom, Aug. 17, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the second quarter ended June 30, 2022 and provided an update on its broad clinical program with its transformative ProTide therapeutics.

Key Points: 
  • EDINBURGH, United Kingdom, Aug. 17, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the second quarter ended June 30, 2022 and provided an update on its broad clinical program with its transformative ProTide therapeutics.
  • As of June 30, 2022, NuCana had cash and cash equivalents of 46.5 million compared to 52.6 million as of March 31, 2022 and 60.3 million at December 31, 2021.
  • NuCana continues to advance its various clinical programs and reported a net loss of 3.9 million for the quarter ended June 30, 2022, as compared to a net loss of 9.1 million for the quarter ended June 30, 2021.
  • Basic and diluted loss per share was 0.07 for the quarter ended June 30, 2022, as compared to 0.17 per share for the quarter ended June 30, 2021.

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

Retrieved on: 
Wednesday, July 27, 2022
Goal, Protide, Notification, GLOBE, U.S. Securities and Exchange Commission, American depositary receipt, Forward-looking statement, PD-1, SEC, Compliance, Private Securities Litigation Reform Act, NASDAQ, Cancer, Company, NCNA, Security (finance), Patient, Terminology, LLC, ADS, Letter, Auction, Pharmaceutical industry, Nasdaq

EDINBURGH, United Kingdom, July 27, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), (NuCana or the Company), announced that it has received a written notification (the Notification Letter) from the Listing Qualifications Department of the Nasdaq Stock Market, LLC (Nasdaq) informing the Company that it has regained compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5450(a)(1) (the Minimum Bid Price Requirement) and the matter is closed.

Key Points: 
  • EDINBURGH, United Kingdom, July 27, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), (NuCana or the Company), announced that it has received a written notification (the Notification Letter) from the Listing Qualifications Department of the Nasdaq Stock Market, LLC (Nasdaq) informing the Company that it has regained compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5450(a)(1) (the Minimum Bid Price Requirement) and the matter is closed.
  • As announced on June 3, 2022, the Company was notified by Nasdaq that it was not in compliance with the Minimum Bid Price Requirement, as the closing bid price of the Company's American Depositary Shares (the "ADSs") had been below $1.00 for 30 consecutive business days.
  • To regain compliance with the Minimum Bid Price Requirement, NuCana was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days.
  • The Notification Letter confirmed that the Company evidenced a closing bid price of the Companys ADSs on Nasdaq at or greater than the $1.00 per ADS minimum requirement for 10 consecutive business days from July 13, 2022 to July 26, 2022 and that the Company has regained compliance with the Minimum Bid Price Requirement.